Evidence map›Paper›PMID 18656518›Full record

ArticleVaccine2008

The contribution of type I interferon signaling to immunity induced by alphavirus replicon vaccines.

Joseph M Thompson, Alan C Whitmore, Herman F Staats, Robert Johnston

Open access · greenAbstract read
In one paragraph

Article in Vaccine, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Lassa Virus Countermeasures.Current topics in microbiology and immunology · 2023
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Joseph M ThompsonDepartment of Microbiology and Immunology, University of North Carolina, Chapel Hill, NC 27599, United States.
Alan C Whitmore
Herman F Staats
Robert Johnston
University of North Carolina at Chapel Hill · USDuke Medical Center · US

Funding

PROTEIN STRUCTURE IN IMMUNOGENICITYP01AI046023 · NIAID · UNIVERSITY OF NORTH CAROLINA CHAPEL HILL · PI JOHNSTON, ROBERT E. · 1999 to 2004
$10.9M
SARS Replicase Proteins in Pathogenesis and ReplicationP01AI059443 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DENISON, MARK R · 2005 to 2009
$9.2M
A Novel Systemic and Mucosal Adjuvant for BiodefenseU01AI070976 · NIAID · GLOBAL VACCINES, INC. · PI JOHNSTON, ROBERT E. · 2006 to 2010
$6.3M
Molecular Biology of Viral Diseases Predoctoral Training GrantT32AI007419 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Mark T Heise, CARY A MOODY · 1993 to 2026
$4.7M
Nasal Vaccines: Mode of Action, Composition & DeliveryR01AI064879 · NIAID · DUKE UNIVERSITY · PI STAATS, HERMAN F · 2006 to 2010
$2.1M
In vitro Construction of Attenuated VEE Virus MutantsR01AI051990 · NIAID · UNIVERSITY OF NORTH CAROLINA CHAPEL HILL · PI JOHNSTON, ROBERT E. · 2001 to 2004
$1.4M
NIAID NIH HHS P01 AI046023NIAID NIH HHS P01-AI046023NIAID NIH HHS P01 AI059443NIAID NIH HHS R01 AI051990NIAID NIH HHS R01-AI051990NIAID NIH HHS R01 AI064879NIAID NIH HHS T32 AI007419NIAID NIH HHS T32-AI007419NIAID NIH HHS U01 AI070976NIAID NIH HHS U01-AI070976
6 · The paper itself

Abstract

The type I interferon (IFN) system is critical for protecting the mammalian host from numerous virus infections and plays a key role in shaping the antiviral adaptive immune response. In this report, the importance of type I IFN signaling was assessed in a mouse model of alphavirus-induced humoral immune induction. Venezuelan equine encephalitis virus replicon particles (VRP) expressing the hemagglutinin (HA) gene from influenza virus (HA-VRP) were used to vaccinate both wildtype (wt) and IFN alpha/beta receptor knockout (RKO) mice. HA-VRP vaccination induced equivalent levels of flu-specific systemic IgG, mucosal IgG, and systemic IgA antibodies in both wt and IFN RKO mice. In contrast, HA-VRP vaccination of IFN RKO mice failed to induce significant levels of flu-specific mucosal IgA antibodies at multiple mucosal surfaces. In the VRP adjuvant system, co-delivery of null VRP with ovalbumin (OVA) protein significantly increased the levels of OVA-specific serum IgG, fecal IgG, and fecal IgA antibodies in both wt and RKO mice, suggesting that type I IFN signaling plays a less significant role in the VRP adjuvant effect. Taken together, these results suggest that (1) at least in regard to IFN signaling, the mechanisms which regulate alphavirus-induced immunity differ when VRP are utilized as expression vectors as opposed to adjuvants, and (2) type I IFN signaling is required for the induction of mucosal IgA antibodies directed against VRP-expressed antigen. These results shed new light on the regulatory networks which promote immune induction, and specifically mucosal immune induction, with alphavirus vaccine vectors.

Indexed as

Adjuvants, ImmunologicAnimalsAntibodies, ViralAntigens, ViralEncephalitis Virus, Venezuelan EquineEnzyme-Linked Immunosorbent AssayGenes, ViralHemagglutinin Glycoproteins, Influenza VirusImmunity, MucosalImmunoglobulin AImmunoglobulin GInfluenza A virusInterferon Type IMiceMice, KnockoutOrthomyxoviridae InfectionsAdjuvants, ImmunologicAntibodies, ViralAntigens, ViralHemagglutinin Glycoproteins, Influenza VirusImmunoglobulin AImmunoglobulin GInterferon Type IOvalbuminViral Vaccines

Identifiers

PMID18656518
PMCPMC3595171
OpenAlexW2022787982

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.